Combination therapy of gastroesophageal reflux disease in comorbidity with functional dyspepsia
https://doi.org/10.31146/1682-8658-ecg-228-8-158-162
Abstract
It has been shown that in patients with GERD and functional dyspepsia, the use of proton pump inhibitors leads to a decrease in heartburn and pain behind the sternum. However, symptoms such as regurgitation, belching, feeling of early satiety and heaviness after eating were stopped ineffectively. The inclusion in the treatment complex of the prokinetic domperidone at a dose of 10 mg 3 times a day contributed to a more effective regression of symptoms of impaired motility of the esophagus and stomach.
About the Authors
M. M. Karimov
Republican Specialized Scientific and Practical Medical Center for Therapy and Medical Rehabilitation
Russian Federation
Russian Federation
P. S. Zufarov
Tashkent Medical Academy
Russian Federation
Russian Federation
G. N. Sobirova
Tashkent Medical Academy
Russian Federation
Russian Federation
M. T. Rustamova
Tashkent Medical Academy
Russian Federation
Russian Federation
D. K. Karimova
Republican Specialized Scientific and Practical Medical Center for Therapy and Medical Rehabilitation
Russian Federation
Russian Federation
S. S. Khairullaeva
Tashkent Medical Academy
Russian Federation
Russian Federation
References
1. De Bortoli N., Martinucci I., Bellini M., Savarino E. Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome. World J Gastroenterol. 2013;19(35):5787-97.
2. Domperidone IND Packet. US Food and Drug Administration. 2018. 17 p. Available at: https: //www.fda.gov/ downloads/drugs/ development approval process/how drugs are developed and approved/appro).
3. Drossman D. Rome III: The functional gastrointestinal disorders. - 3rd ed. - McLean, VA: Degnon Associates, Inc., 2006. pp. 369-418.
4. Keohane J., Quigley E. M. Functional dyspepsia and nonerosivereflux disease: clinical interactions and their implications. Med Gen Med. 2007;9(3):31.
5. Ortiz A., Cooper C. J., Alvarez A. Cardiovascular Safety Profile and Clinical Experience with High-Dose Domperidone Therapy for Nausea and Vomiting. Am. J. Med. Sci. 2015;349 (5):421-424.
6. Parkman H.P., Jacobs M. R., Mishra A. Domperidone Treatment for Gastroparesis: Demographic and Pharmacogenetic Characterization of Clinical Efficacy and Side-Effects Digestive Diseases and Sciences. Dig. Dis. Sci. 2011;56 (1):115-124.
7. Schey R., Saadi M., Midani D. Domperidone to Treat Symptoms of Gastroparesis: Benefits and Side Effects from a Large Single-Center Cohort. Dig. Dis. Sci. 2016;61(12):3545-3551.
8. Wolfe M.M., Lowe R. C. Investing in the Future of GERD. J. Clin. Gastroenterol. 2007;41:209.
9. Yuan Y., Hunt R. H.Intragastric acid suppressing effect of proton pump inhibitors twice daily at steady state in healthy volunteers: evidence of an unmet need? Am. J. Gastroenterol. 2008;103 (suppl 1):50. Abstract #128.
Review
For citations:
Karimov M.M., Zufarov P.S., Sobirova G.N., Rustamova M.T., Karimova D.K., Khairullaeva S.S. Combination therapy of gastroesophageal reflux disease in comorbidity with functional dyspepsia. Experimental and Clinical Gastroenterology. 2024;(8):158-162. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-228-8-158-162
Views:
423
Email this article 